Skip to main content

SECURE-Cirrhosis is pleased to be officially endorsed by the AASLD

Full manuscripts available here:

Outcomes in Chronic Liver Disease and Cirrhosis Patients (Journal of Hepatology)

Outcomes in Liver Transplant Recipients (Lancet Gastro Hep)


For cases outside of North or South America, China/Japan/Korea please visit our collaborators at The EASL


Dear Colleagues,

Given the interest in the emerging and evolving coronavirus (COVID-19) epidemic and the questions regarding how this will impact patients with chronic liver disease and post-liver transplantation, we created a secure, online, de-identified Personal Health Identifier (PHI)-free reporting registry.  We encourage clinicians taking care of patients with liver diseases worldwide to report ALL cases of COVID-19 in patients with chronic liver disease (with and without cirrhosis) and post-liver transplant, regardless of severity of COVID-19 (including asymptomatic patients detected through public health screening).  Reporting a case to this Surveillance Epidemiology of Coronavirus) Under Research Exclusion (SECURE)-CIRRHOSIS registry should take approximately 5 minutes.  With the collaboration of our entire hepatology community, we will rapidly be able to define the impact of COVID-19 on patients with chronic liver diseases and post-liver transplantation and how factors such as age, comorbidities, and immunosuppression impact COVID outcomes.

Key points:

  1. This is an international effort—we are counting on robust participation and collaboration. We are working alongside our European partners Covid-Hep to learn more about the global impact of COVID-19 in patients with liver diseases.
  2. On the project website, we will provide regularly updated summary information about reported cases, including numbers of cases by country, number of cases by comorbidities etc. so the entire hepatology community has access to these data.
  3. The registry contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.
  4. The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

We hope you will actively contribute to this voluntary reporting system. Through broadscale participation and collaboration, we will be able to answer these very pressing questions for our chronic liver disease and post-liver transplantation patients and their caregivers.

To report a case of coronavirus, click here.

If you have any questions, please reach out to

In addition to the reporting cases of COVID-19 to SECURE-CIRRHOSIS, we also encourage reporting to your local public health agency where applicable.


Andrew M. Moon, MD, MPH (Gastroenterology/Hepatology Fellow, University of North Carolina at Chapel Hill)

A. Sidney Barritt IV, MD, MSCR (Medical Director of Liver Transplant, University of North Carolina at Chapel Hill)

Renumathy Dhanasekaran, MD, PhD (Transplant Hepatologist, Stanford University)

Nneka N. Ufere, MD (Gastroenterology/Hepatology Fellow, Massachusetts General Hospital)

Ponni Perumalswami, MD (Transplant Hepatologist, Icahn School of Medicine at Mount Sinai)

Patricia D. Jones, MD (Transplant Hepatologist, University of Miami)

Feng Su, MD (Transplant Hepatology Fellow, University of Washington)